SLC5A2 and diabetes mellitus: Anti-inflammatory and antifibrotic effects are achieved through the reduction of levels of NFkB, urinary and serum IL-6, urinary and serum MCP-1, and serum TNFR1. Additionally, SGLT2 inhibitors may reduce serum uric acid levels in patients with type 2 diabetes mellitus.